This meeting took place in 2018

Here are the related meetings in 2019:
Genome Engineering: From Mechanisms to Therapies (B4)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Precision Genome Editing with Programmable Nucleases (B1)

Organizer(s) Jin-Soo Kim, Feng Zhang and Daniel F. Voytas
January 28—February 1, 2018
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Oct 3, 2017
Abstract Deadline: Nov 1, 2017
Scholarship Deadline: Oct 3, 2017
Discounted Registration Deadline: Dec 5, 2017

Sponsored by Editas Medicine, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated

Summary of Meeting:
Genome editing refers to the use of programmable DNA-targeting platforms to manipulate genetic and epigenetic information in living cells and organisms. Genome editing has been recently democratized by the development of RNA-guided endonucleases repurposed from CRISPR-Cas microbial defense systems against viruses or plasmids. Whereas novel tools such as Cpf1 and RNA-guided deaminases are being developed to expand the scope of genome editing, old tools such as ZFNs and TALENs are likely to undergo innovations as well. These tools enable genome-wide genetic screens in cell lines and genetic studies in both model and non-model organisms. Furthermore, genome editing holds great promise for broad applications in medicine and biotechnology, raising public interest and concerns. Yet genome editing is still limited by many factors such as inefficient delivery in vivo, off-target effects, and unwanted, alternative DNA repair. This conference offers opportunities to learn about new developments, advancements and applications in the field.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Jarryd Campbell
Mayo Clinic, USA

Eirini Margarita Kallimasioti-Pazi
Institute of Genetics and Molecular Medicine, Scotland

Grace Mullally
University of Bristol, UK